Press Releases Rallybio Corporation

Equities

RLYB

US75120L1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.85 ^USD	+8.82%		+4.52%	-22.59%

Apr. 17	Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting	CI
Apr. 12	Top Premarket Decliners	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting	Apr. 17	BU
Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB	Apr. 15	AQ
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)	Apr. 10	BU
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting	Apr. 01	BU
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 12	BU
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 26	BU
Rallybio Announces Portfolio Prioritization and Provides Corporate Update	Feb. 06	BU
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024	Jan. 04	BU
Rallybio : RLYB116 Conference Call	Dec. 20	PU
Rallybio : RLYB116 Presentation	Dec. 20	PU
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5	Dec. 20	BU
Affibody’s Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116	Dec. 20	AQ
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting	Dec. 11	AQ
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting	Dec. 09	BU
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia	Nov. 28	BU
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates	Nov. 09	BU
Rallybio to Present at Upcoming Investor Conferences in November	Nov. 08	BU
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting	Nov. 02	BU
Rallybio to Present at the JonesTrading 2023 Healthcare Summit	23-10-03	BU
Rallybio : 2023 Cantor Global Healthcare Conference	23-09-28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Rallybio Corporation

Equities

RLYB

US75120L1008

Press Releases

Filters